Palo Alto - Paul Hastings LLP, a leading global law firm, announced today that it represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $63.25 million underwritten public offering of common stock. Viking announced that it intends to use the net proceeds from the financing for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes.
Palo Alto corporate partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associate Ed Chu.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.
+1 212 318 6946
+1 212 318 6512
U.S. Real Estate and Corporate
+1 212 318 6513
U.S. Litigation and Employment
+1 212 318 6525
Europe & Asia
+44 20 3023 5238
Receive insights from our lawyers on legal issues in today's complex environment.